ALDEYRA THERAPEUTICS INC

CEO Brady Todd’s June 3 buy of 250,000 Aldeyra shares at $1.67 shows insider confidence amid a 6.86% weekly dip, hinting at potential upside if pipeline progress or conference news spur a rebound.

Insider buys at Aldeyra suggest potential upside, but institutional sales and bearish options warn investors to stay cautious.

Aldeira CFO’s recent 5,000‑share purchase at $1.42 signals confidence amid steep price declines, hinting insiders see value below the 52‑week low.